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Introduction
In the United States, heart failure (HF) is the fourth leading cause of all hospitalizations and the lead-ing cause of hospitalization among cardiovascular 
diagnoses.1 According to Medicare, approximately 
one in four patients with a HF hospitalization will be 
readmitted at 30 days.2 Readmissions are a target for 
researchers and policy makers, as they are perceived 
as a marker of poor care quality and a source of pre-
ventable health care utilization. With HF prevalence 
projected to increase from 5.7 million to over 8 million 
American adults and costs ballooning from $20.9 bil-
lion to $53.1 billion between 2012 and 2030, reduc-
ing preventable hospitalizations for HF patients is a 
national priority.2,3 
 Medicare uses hospital performance on 30-day 
HF mortality and readmissions as a quality metric and 
applies financial penalties to hospitals based on per-
formance. Yet, strategies for effectively preventing or 
reducing readmissions are not agreed upon. Further-
more, the 30-day period of observation for readmis-
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sion after hospitalization is arbitrary and a multitude 
of factors external to the quality of inpatient care may 
influence a patient’s readmission risk. Nevertheless, 
care systems must prioritize reducing all avoidable 
hospitalizations whether initial or repeated. This ar-
ticle will discuss strategies for preventing HF readmis-
sions, highlighting both challenges and opportunities.
Heart failure hospitalizations
A hospital admission for HF portends a high risk for 
future morbidity and mortality. Among Medicare pa-
tients admitted for HF, 67% experienced a readmis-
sion and 36% died within 1 year. Readmission risk 
is highest on the third day following discharge. Not 
until 38 days after discharge is the readmission risk 
cut in half.4 Whereas hospital length of stay and inpa-
tient mortality have decreased in the United States, 
discharges to skilled nursing facilities have increased 
(Figure 1).5 This reflects a sizeable population of 
chronically ill HF patients unable to live independently 
and at high readmission risk. The quality of a skilled 
nursing facility is known to influence hospital readmis-
sion rates, as well as mortality.6
 HF management protocols prioritize cardiovas-
cular care; only 17% to 35% of HF discharges are 
readmitted with a repeat HF exacerbation; however, 
47% to 62% are readmitted for noncardiovascular 
causes.7,8 The diversity of readmission etiologies em-
phasizes the importance of a comprehensive assess-
ment to prevent complications from other comorbidi-
ties and to identify specific patient needs. With the 
implementation of financial incentives to reduce re-
admissions, Medicare has reported modest decreas-
es in the average 30-day HF readmission rate (Fig-
ure 2).9,10  The corresponding fall in the readmission 
rate also correlated with an increase in “observational 
stays,” which are not categorized as readmissions. 
The degree to which readmissions in HF patients 
are preventable is unclear. Less than a quarter of all 
30-day readmissions were estimated as potentially 
avoidable based on chart review.11 
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Fig. 1 Disposition at discharge for primary heart failure admissions in the United States.  *Data estimated from the National Inpatient 
Sample.
Abbreviations: Home/Home health, discharged home or with home health care services; SNF/ICF, discharged to skilled nursing facility, intermediate care 
facility, or another type of facility; Short-term hospital, transfer; Died, inpatient death.
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Medical therapy to reduce HFrEF readmissions
The management of HF with reduced ejection frac-
tion (HFrEF) has evolved over recent decades with 
additional medical therapies and interventions that 
improve long-term survival. A strong foundation ex-
ists for the use of evidence-based medical therapies 
to improve outcomes and reduce the hospitalization 
burden for HFrEF patients (Table I).12 Therapies that 
reduce the hospitalization burden are expected to re-
duce readmissions as well. 
 The cornerstone of guideline-directed medical 
therapy for HFrEF includes the inhibition of the renin-
angiotensin and cardiac β-adrenergic systems.13,14 
Angiotensin-converting enzyme (ACE) inhibitor or 
angiotensin II receptor blocker (ARB) were found in 
clinical trials to improve mortality and reduce hospital-
izations.15,16 β-Blockers are effective in reducing both 
mortality and readmissions.17-19 Of the performance 
measures recommended by the American College of 
Cardiology and the American Heart Association, only 
β-blockers and ACE inhibitors/ARB were significantly 
associated with reductions in mortality and readmis-
sions.20 The new angiotensin II receptor neprilysin in-
hibitor (ARNI) sacubitril-valsartan improved mortality 
and hospitalization risk beyond the benefits of ACE 
inhibition among symptomatic HFrEF patients in the 
large PARADIGM-HF trial (Prospective comparison of 
ARNI with ACEI to Determine Impact on Global Mor-
tality and morbidity in Heart Failure).21 Both American 
and European guidelines endorse the use of ARNIs in 
appropriately selected patients.13,14  
 Additional medical therapies have been found to 
reduce hospitalization risk. Aldosterone inhibitors such 
as spirinolactone and eplerenone have both been 
shown in clinical trials to reduce death and hospital-
izations, with benefits seen within 30 days of therapy 
initiation.22,23 Observational data confirms that the ad-
dition of an aldosterone inhibitor reduces HF readmis-
sions, but remains underutilized in clinical practice.24 
Among African Americans with HFrEF, the combina-
tion of hydralazine and isosorbide dinitrate was found 
to improve mortality and reduce hospitalizations on top 
of optimal medical therapy.25 Optimization of guideline-
directed medical therapy dosing and monitoring is also 
essential for improving outcomes, and better ensuring 
the efficacy of therapies demonstrated in trials trans-
lates into real-world clinical effectiveness.
 HFrEF patients with elevated heart rates are ob-
served to be at increased risk for adverse outcomes.26 
A new sodium-potassium inward channel (If, also called 
the funny current) blocker, ivabradine, was found to re-
duce hospitalizations for medically optimized HFrEF 
patients with a sinus rate greater than 70 beats per 
minute.27 Although an older medication, there is fair 
evidence for recommending digoxin as an add-on 
therapy in symptomatic or at-risk patients. The Digi-
talis Investigators Group trial found a 6% absolute risk 
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Fig. 2 Trends in the median hospital risk-standardized readmission rates for Medicare heart failure patients.
Based on data sourced from reference 10: Centers for Medicare and Medicaid Services. Hospital Quality Initiative: Outcome Measures. Chartbook 2013-
2017 (2017). Available at https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/HospitalQualityInits/OutcomeMeasures.html. 
Accessed December 2017.
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reduction in hospitalization with digoxin after an aver-
age of 37 months of follow-up.28 Although β-blockers 
were not routinely used during the study period, more 
recent observational data suggest that digoxin may 
be effective in reducing readmissions.29 With respect 
to diuretic therapy, torsemide has a higher bioavailabil-
ity compared with furosemide. Small nonblinded trials 
suggest that patients discharged with torsemide have 
a lower readmission risk.30 
 Nutritional supplementation with n-3 polyunsatu-
rated fatty acids was found to provide a small mor-
tality and hospitalization benefit after a median ob-
servation period of 3.9 years.31 Lifestyle interventions 
through exercise were evaluated in the HF-ACTION 
trial (Heart Failure: A Controlled Trial Investigating 
Outcomes of exercise traiNing).32 The addition of a 
regimented exercise program reduced HF hospital-
izations and improved quality of life. Pooled findings 
from other monitored exercise trials facilitated Medi-
care’s approval of cardiac rehabilitation in chronic 
HFrEF patients.33 
 Whereas device therapies such as implantable 
cardioverter defibrillators (ICD) are indicated for the 
prevention of sudden cardiac death, cardiac resyn-
chronization therapy (CRT) is useful for improving car-
diac function and symptoms. In the trials CARE-HF 
(CArdiac REsynchronization-Heart Failure) and MA-
DIT-CRT (Multicenter Automatic Defibrillator Implan-
tation Trial with Cardiac Resynchronization Therapy), 
CRT markedly reduced HF hospitalization risk.34,35 
When compared with ICD therapy alone, CRT ther-
apy is associated with a lower risk of death and all-
cause readmission.36
 The potential for new technologies to monitor 
congestion and prevent readmissions is a developing 
field. The CardioMEMS device (St. Jude Medical, Inc, 
St. Paul, Minnesota) is the first implantable pulmo-
nary artery sensor that wirelessly transmits pulmonary 
artery hemodynamics to monitor cardiac pressures. 
Usage of the device reduced HF hospitalizations by 
37% after 15 months among patients previously hos-
pitalized for HF compared with usual care.37 Both the 
fidelity of data and an advanced care team receiving 
the transmitted information resulted in improved fluid 
management and patient outcomes.
 In patients with HF with preserved ejection frac-
tion (HFpEF), no therapy has been shown to reduce 
mortality. However, there is some data to suggest that 
aldosterone antagonist therapy may reduce HF hos-
pitalization risk in these patients. Implantable hemo-
dynamic monitoring also has been demonstrated to 
reduce HF hospitalizations.36
Hospital interventions to reduce readmissions
Transforming care delivery to provide more informa-
tion and resources to discharged patients has also 
been associated with lower readmission rates. A re-
view of interventions (such as patient education, dis-
charge planning, medication reconciliation, schedul-
ing follow-up before discharge, communication with 
outpatient providers, and follow-up telephone calls) 
implemented to reduce readmissions found that 
no single intervention alone reduced the 30-day re- 
admission risk. Generally, more interventions are as-
Trial
Exercise
Cardiac rehabilitation HF-ACTION
Drug
ACE inhibitor SOLVD
ARB CHARM
ARNI PARADIGM-HF
b-Blockers CIBIS-II, MERIT-HF, 
COPERNICUS
Mineralocorticoid antagonist RALES, EPHESUS-HF
Ivabradine SHIFT
Digoxin DIG
Hydralazine-isosorbide 
dinitrate
A-HeFT
n-3 PUFA GISSI-HF
Devices
CRT CARE-HF, MADIT-CRT
CardioMEMS CHAMPION
Table I Therapies shown to reduce heart failure hospitalization risk 
in clinical trials on heart failure with reduced ejection fraction.
Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin II 
receptor blocker; ARNI, angiotensin II receptor neprilysin inhibitor; n-3 PUFA, 
n-3 polyunsaturated fatty acids; CRT, cardiac resynchronization therapy
Trial names: A-HeFT, African-American Heart Failure Trial; CARE-HF, 
CArdiac REsynchronization - Heart Failure; CHAMPION, CardioMEMS Heart 
sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class 
III heart failure patients; CHARM, Candesartan in Heart failure: Assessment 
of Reduction in Mortality and morbidity; CIBIS-II, Cardiac Insufficiency 
Bisoprolol Study II; COPERNICUS, CarvedilOl ProspEctive RaNdomIzed 
CUmulative Survival; DIG, Digitalis Investigation Group; EPHESUS-HF, 
Eplerenone Post–Acute Myocardial Infarction Heart Failure Efficacy and 
Survival Study; GISSI-HF, Gruppo Italiano per lo Studio della Sopravvivenza 
nell’Infarto miocardico; HF-ACTION, Heart Failure: A Controlled Trial 
Investigating Outcomes of exercise traiNing; MADIT-HF, Multicenter 
Automatic Defibrillator Implantation Trial with cardiac resynchronization 
therapy; MERIT-HF, MEtoprolol CR/XL Randomised Intervention Trial in 
congestive Heart Failure; PARADIGM-HF, Prospective comparison of ARNI 
with ACE-I to Determine Impact on Global Mortality and morbidity in Heart 
Failure trial; RALES, Randomized ALdactone Evaluation Study; SHIFT, 
Systolic Heart failure treatment with the If inhibitor ivabradine Trial; SOLVD, 
Studies Of Left Ventricular Dysfunction. 
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sociated with greater success.38 Most research in this 
realm has been observational, and further research 
is warranted in order to understand the effectiveness 
and costs of resource intensification. 
 Certain hospital characteristics have been as-
sociated with lower readmission risks. Higher nurse 
staffing ratios were associated with 41% lower odds 
of receiving Medicare penalties for excessive re- 
admissions when controlling for case-mix and hospi-
tal characteristics.39 Hospitals with a greater propor-
tion of patients receiving follow-up care within 7 days 
of discharge have a lower risk of 30-day mortality and 
readmission, controlling for patient and hospital fac-
tors.40 Appropriate follow-up after hospitalization re-
mains integral to reducing repeat hospitalizations.
 Peri-discharge interventions may improve clinical 
outcomes and reduce HF readmissions, as shown in 
small trials. A multidisciplinary, nurse-directed interven-
tion including comprehensive education for patients 
and families, medication review, and intensive follow-
up reduced readmissions by over half and improved 
quality of life scores.41 Another small randomized 
trial found formal education that used nurse-directed 
patient education and intermittent patient contact 
after discharge for 1 year reduced readmissions by 
39%.42 A meta-analysis of interventions among older 
HF patients reported that comprehensive discharge 
planning with post-discharge support reduces re- 
admissions and improved outcomes without increas-
ing costs.43 Publication bias remains a concern re-
garding the external validity of these interventions, 
especially for smaller studies. Overall, the literature 
suggests that more support and careful outpatient 
monitoring may reduce the readmission burden and 
improve patient quality of life. 
Perspective on HF readmission reduction efforts 
Whether the 30-day HF readmission is an appropri-
ate metric of hospital care quality is debatable. Critics 
have argued that the 30-day readmission measure 
does not adjust for medical complexity, disability, and 
socioeconomic status. Models that risk adjust on the 
basis of characteristics during hospitalization per-
form poorly, with C-statistics well below acceptable 
discrimination standards.44 Hospitals in lower socio-
economic regions are disadvantaged and more likely 
to receive Medicare penalties.45-47 Over half of the 
national variation in hospital readmission rates may 
be explained by the county socioeconomic factors.48 
Financially penalizing hospitals that have limited re-
sources is a perverse disincentive that may exacer-
bate disparities in the quality of care delivered.
 Nearly half of HF patients are readmitted for non-
cardiovascular conditions. The importance of a com-
plete medical evaluation should be emphasized, as 
HF is only one of many comorbidities that may in-
crease the readmission risk. A HF hospitalization 
should not only address the acute cardiovascular is-
sues. Before discharge, outpatient challenges should 
be evaluated. Patients should have an assessment 
of their comorbid conditions, health literacy, cognitive 
impairment, mental health, financial barriers, func-
tional status, and be provided early outpatient follow-
up.49 The potential impact that such multidimensional 
assessments and interventions may have on rehospi-
talization risk for HF patients requires further evalua-
tion in clinical trials. 
Conclusions
A number of medical and device therapies are known 
to improve HF outcomes in HFrEF patients and to re-
duce readmission risk. These therapies are frequently 
underutilized in eligible patients. Hospital strategies 
that increase support at discharge, improve com-
munication, and provide close outpatient follow-up 
are associated with lower readmission risk. Whether 
the 30-day readmission rate is an appropriate qual-
ity metric for inpatient care is debatable. Evidence 
suggests that variations in hospital performance are 
mostly unexplained and may relate to patient and re-
gional factors. Nevertheless, a hospitalization is a ma-
jor life event that portends future adverse outcomes. 
All potentially avoidable hospitalizations should be 
prevented through careful outpatient HF manage-
ment. Health system strategies that improve the qual-
ity of care and reduce the hospitalization burden are 
needed and require further research. L
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